

**The 1st Joseph Markoff, PhD, MD Endowed Lecture: Reza Dana, MD, MSc, MPH**

**Friday, April 11, 2025**

*Wills Eye Auditorium*

**Conference Description:**

[Click Here to Register for the Livestream](https://attendee.gotowebinar.com/register/7208271132061989467)

Guest Lecture:

**New Ways of Doing Old Things: Translational Investigations in Management of Common Corneal and Ocular Surface Disorders**  
*Reza Dana, MD, MSc, MPH* **Harvard Ophthalmology***Vice Chair for Academic Programs  
Director, Harvard-Vision Clinical Scientist Development Program  
Co-director, Cornea Center of Excellence***Harvard Medical School***Member, PhD Program in Immunology, Harvard University***Mass Eye and Ear***Director, Cornea and Refractive Surgery Service  
Senior Scientist (Schepens Eye Research Institute)   
Associate Chief for Academic Programs*

Program Chair:  
**Leslie Hyman, PhD**

**At the conclusion of the course, participants should be able to:**

1 Describe the most common approaches to treating corneal and ocular surface disorders.

1 Apply modern innovations to established treatments of corneal disease.

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Zeba A. Syed, MD | Planner | Speakers Bureau-Bio-Tissue|Advisor-Bio-Lattice|Consulting Fee-Bruder|Grant or research support-Dompé |Speakers Bureau-Tarsus|Consulting Fee-Glaukos Corporation|Consulting Fee-Recordati - 01/28/2025 |
| Leslie Hyman, PhD | Peer Reviewer, Planner | Nothing to disclose - 03/18/2025 |
| Natasha Kolomeyer, MD | Planner | Consulting Fee-Allergan (Relationship has ended)|Consulting Fee-Thea (Relationship has ended)|Grant or research support-Guardion Health Services Inc (Relationship has ended)|Grant or research support-Equinox|Grant or research support-Nicox|Grant or research support-Olleyes|Grant or research support-Santen Pharmaceuticals|Grant or research support-Glaukos Corporation|Grant or research support-Diopsys|Grant or research support-Aerie Pharmaceuticals - 02/07/2025 |
| Sarah Pyfrom, PhD | Planner | Nothing to disclose - 04/19/2024 |
| Reza Dana, MD, MPH | Faculty | Consulting Fee-Amgen (Relationship has ended)|Private Corp Stock-Aramis Biosciences|Private Corp Stock-Claris Biotherapeutics - 02/12/2025 |

